Morpholino-mediated increase in soluble flt-1 expression results in decreased ocular and tumor neovascularization
AssigneeUniversity of Utah Research Foundation
InventorsBalamurali K. Ambati, Hironori Uehara
Life of this patent
Estimating the term…
Abstract
Methods of inhibiting lymphangiogenesis and/or angiogenesis in a subject are provided. In one aspect, for example, a method of inhibiting angiogenesis in a subject can include binding an antisense morpholino to an mRNA splicing site of VEGFR1 selected from exon13_intron13 junction, intron13_exon14 junction, or a combination thereof. In another aspect, the morpholino includes a member selected from VEGFR1_MOe13, VEGFR1_MOi13, or a combination thereof.
Claims20
A method of inhibiting angiogenesis in a subject, comprising:
- binding an antisense morpholino to a splicing site of VEGFR1 mRNA selected from the group consisting of exon13_intron13 junction, intron13_exon14 junction, or a combination thereof such that the VEGFR1 mRNA is spliced into an sFlt-1 isoform.
A pharmaceutical composition for inhibiting angiogenesis in a subject, comprising:
- a pharmaceutically effective carrier including a morpholino capable of binding to a splicing site of VEGFR1 mRNA selected from the group consisting of exon13_intron13 junction, intron13_exon14 junction, or a combination thereof to facilitate increased expression of sFlt-1.
Dependencies are inferred from the claim text.